Cardiotoxicity of epirubicin versus doxorubicin: cost and clinical results.
Ventura
Gerard J
GJ
D000903:Antibiotics, Antineoplastic / Q000191:economics* / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D001943:Breast Neoplasms / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D003362:Cost-Benefit Analysis; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000009:adverse effects* / Q000191:economics* / Q000627:therapeutic use; D016527:Drug Costs; D004345:Drug Industry; D015251:Epirubicin / Q000008:administration & dosage / Q000009:adverse effects* / Q000191:economics* / Q000627:therapeutic use; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006321:Heart / Q000187:drug effects; D006333:Heart Failure / Q000139:chemically induced*; D006801:Humans
D000903:Antibiotics, Antineoplastic; D015251:Epirubicin; D004317:Doxorubicin; D003520:Cyclophosphamide; D005472:Fluorouracil